MediWound, a biotech firm that makes burn and wound treatments, is ready to start a clinical trial in three US medical centers of a new possible drug to treat non-melanoma skin cancer.
The clinical trial, scheduled to start in the second quarter of the year, will study the safety, tolerability and efficacy of the drug product candidate MWPC005 for the non-invasive treatment of basal cell carcinoma (BCC). This is a non-melanoma skin cancer that arises from the basal layer of epidermis and its appendages.
The move represents a pivot from burn-related wounds, on which Mediwound has focused until now. The firm develops and produces therapies based on proteolytic enzymes which it extracts from the stem of the pineapple plant.
MediWound’s lead drug, NexoBrid, is a gel based on pineapple enzymes for the treatment of burns. The firm’s second product, EscharEx, is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds.
Photo source: Dreamstime.com